Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 23;6(1):314.
doi: 10.1038/s41392-021-00722-0.

Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs

Zhihui Zhang  1   2 , Nan Sun  3   4 , Jie He  5   6
Affiliations
Comment

Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs

Zhihui Zhang et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Comment on

  • Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
    Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Kelly RJ, et al. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. N Engl J Med. 2021. PMID: 33789008 Clinical Trial.

References

    1. Kelly RJ, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 2021;384:1191–1203. doi: 10.1056/NEJMoa2032125. - DOI - PubMed
    1. Zhang C, et al. An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. Signal Transduct. Target Ther. 2020;5:182. doi: 10.1038/s41392-020-00221-8. - DOI - PMC - PubMed
    1. Mokdad AA, et al. Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: a propensity score-matched analysis. JAMA Oncol. 2018;4:31–38. doi: 10.1001/jamaoncol.2017.2805. - DOI - PMC - PubMed
    1. Yang H, et al. The combination options and predictive biomarkers of PD-1/PD-L1 inhibitors in esophageal cancer. Front Oncol. 2020;10:300. doi: 10.3389/fonc.2020.00300. - DOI - PMC - PubMed
    1. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann. Oncol. 2021;32:590–599. doi: 10.1016/j.annonc.2021.02.004. - DOI - PubMed

Publication types

MeSH terms